Treatment studies
tested Western Aphasia Battery score, NIHSS score, Modified Rankin Scale, Barthel Index at Day 90
result Cerebrolysin+SLT showed significant improvement in Western Aphasia Battery (p<0.001) and NIHSS (p<0.001); mRS and Barthel Index also improved at Day 90.
Published human study (PubMed / Europe PMC), extracted from its abstract — not a CT.gov-registered trial.
Treatment studies
tested any hemorrhagic transformation and symptomatic HT within 14 days; timing of safe anticoagulation resumption
result HTI>0: symptomatic HT HR=0.245 (95%CI 0.072–0.837, p=0.020); any HT HR=0.543 (95%CI 0.297–0.991, p=0.032); anticoagulation restart 1–2 days earlier vs control.
Published human study (PubMed / Europe PMC), extracted from its abstract — not a CT.gov-registered trial.
Treatment studies
tested symptomatic and any hemorrhagic transformation over 14 days; hazard dynamics and safe anticoagulation timing
result Cerebrolysin reduced symptomatic HT (HR=0.245, 95% CI 0.072–0.837, p=0.020) and any HT (HR=0.543, 95% CI 0.297–0.991, p=0.032) in high-risk patients; advanced risk-equilibrium by 1–2 days.
Published human study (PubMed / Europe PMC), extracted from its abstract — not a CT.gov-registered trial.
RCTNCT00840671Phase 3 · 2005 · n=119 · Ever Neuro Pharma GmbH Stroke
tested Modified Rankin Scale score at day 90 (or earlier in the event of patient withdrawal).
result Completed; results not posted
RCTNCT00868283Phase 4 · 2006 · n=1071 · Ever Neuro Pharma GmbH Ischemic Stroke
tested Modified Rankin Scale
result Completed; results not posted
RCTNCT00911807Phase 2 · 2004 · n=217 · Ever Neuro Pharma GmbH Alzheimer Disease
tested Change From Baseline in Alzheimer's Disease Assessment Scale Cognitive Subpart (Extended Version) (ADAS-COG+) at Week 28
RCTNCT00947531Phase 4 · 2006 · n=242 · Ever Neuro Pharma GmbH Vascular Dementia
tested Change From Baseline in ADAS-cog+ (Alzheimer's Disease Assesment Scale - Cognitive Subpart) at Week 24
result −6.1 points on a scale (Change From Baseline in ADAS-cog+ (Alzheimer's Dis…)
RCTNCT01388738Phase 3 · 2011 · n=30 · Clinical Institute of the Brain, Russia Stroke
tested MEP(motor evoked potential) parameter: motor threshold
result Completed; results not posted
RCTNCT01606111Phase 4 · 2013 · n=46 · Ever Neuro Pharma GmbH Traumatic Brain Injury
tested Composite endpoint of mean score in MMSE, PSI, Stroop Color-Word Test, Early Reha BI, GOS-E
result Terminated before completion
Terminated: Poor patient recruitment
RCTNCT01787123Phase 2 · 2013 · n=50 · Kwong Wah Hospital Subarachnoid Hemorrhage
tested Global functional performance
result Completed; results not posted
Alzheimer Disease
tested Change from Baseline in ADAS-cog. and CIBIC+ score distribution
result Withdrawn before enrolment
Withdrawn before enrolment; no public reason provided.
RCTNCT01996761Phase 4 · 2011 · n=71 · Samsung Medical Center Cerebrolysin
tested the improvement ratio of Fugl-Meyer assessment
result Completed; results not posted
RCTNCT02116348Phase 2 · 2014 · n=100 · Ain Shams University Cerebral Palsy Children
tested neurodevelopment
result In progress (unknown)
RCTNCT02149875Phase 1 · 2010 · n=84 · Shanghai 6th People's Hospital Acute Cerebral Stroke Within 12 Hours for the First Time
tested National Institutes of Health Stroke Scale Score
result −1.0 units on a scale (National Institutes of Health Stroke Scale Score)
RCTNCT02581371Phase 4 · 2015 · n=30 · Clinical Institute of the Brain, Russia Ischemic Stroke
tested Overall dynamics of the hand function assessed by the Frenchay Arm Test
result In progress (unknown)
RCTNCT02768571Phase 4 · 2016 · n=80 · Samsung Medical Center Stroke
tested Score of Fugl-Meyer assessment (FMA)
result Completed; results not posted
RCTNCT03506841Phase 1 · 2016 · n=60 · Mansoura University Children Hospital Infant Development
tested Neurodevelopmental outcome
result Completed; results not posted
RCTNCT04124367Phase 2 · 2021 · n=4 · Ever Neuro Pharma GmbH Chronic Stroke
tested Action Research Arm Test (ARAT)
result Terminated before completion
Terminated: for strategic and pandemic reasons
RCTNCT04427241Phase 4 · 2023 · n=12 · Konkuk University Medical Center Disorder of Consciousness
tested Coma Recovery Scale - revised
result In progress (recruiting)
RCTNCT04751136Phase 2 · 2016 · n=64 · Mansoura University Children Hospital Down Syndrome
tested Rate of neurocognitive development
result Completed; results not posted
RCTNCT04830943Phase 3 · 2020 · n=250 · Assiut University Covid19 Related Anosmia and Aguesia
tested The smell and taste questionnaire component of the National Health and Nutrition Examination Survey (NHNES). And the modified Arabic translated and validated sniffin' sticks odor identification test was used for objective olfactory evaluations.
result Completed; results not posted
RCTNCT04913831Phase 4 · 2021 · n=30 · Yonsei University Stroke
tested CRS-R (JFK Coma recovery scale-revised)
result In progress (unknown)
RCTNCT05124353Phase 2 · 2021 · n=100 · Pomeranian Medical University Szczecin Stroke, Acute, Ischemic
tested Survival
result In progress (unknown)
RCTNCT05755997Phase 2 · 2023 · n=30 · Ever Neuro Pharma GmbH Cadasil
tested Change in cognitive battery (RAVLT)
result In progress (active-not-recruiting)
RCTNCT05821075Phase 1 · 2023 · n=90 · October 6 University Bell Palsy
tested change in scores of the house Brackman grading system HB
result In progress (recruiting)
RCTNCT058646772023 · n=100 · Medical University of Lublin Cognitive function in aging
tested The primary end-point is to analyze changes in CAM-ICU test the incidence of delirium on the postoperative day 5.
result In progress (unknown)
RCTNCT06052787Phase 3 · 2023 · n=150 · Ain Shams University Traumatic Brain Injury
tested The Glasgow Coma Scale (GCS)
result Completed; results not posted
RCTNCT06208540Phase 4 · 2021 · n=160 · Sherifa Ahmed Hamed Post-covid-19 Persistent Smell and Taste Disorders
tested subjective evaluation
result Completed; results not posted
RCTNCT06273020Phase 4 · 2022 · n=60 · Hospital Universitario Dr. Jose E. Gonzalez Ischemic Stroke, Acute
tested Blood-Brain-Barrier Permeability after 10-14days of cerebrolysin in patients with AIS of the middle cerebral artery
result In progress (unknown)
RCTNCT06339411Phase 2 · 2026 · n=100 · Chang Gung Memorial Hospital Acute Ischemic Stroke
tested Final Infarct Volume on Diffusion-Weighted MRI
result In progress (recruiting)
RCTNCT066775022024 · n=500 · Medical University of Lublin Cognitive function in aging
tested CAM-ICU test
result In progress (recruiting)
RCTNCT06899464Phase 4 · 2025 · n=30 · Cardinal Stefan Wyszynski University Intracerebral Hemorrhage
tested Efficacy Outcome
result In progress (recruiting)
Treatment studies
tested hemorrhagic transformation rate, NIHSS at 24h and day 14, mRS at day 90
result Symptomatic HT reduced (OR 0.248, 95% CI 0.072–0.851, p=0.019); NIHSS improved at day 14 (p=0.045); no significant mRS difference at day 90 but trend toward improvement.
Published human study (PubMed / Europe PMC), extracted from its abstract — not a CT.gov-registered trial.
Treatment studies
tested all-cause death, serious adverse events, non-death attrition, adverse events
result No benefit on all-cause death (RR 0.96, 95% CI 0.65–1.41; moderate certainty); non-fatal SAEs increased (RR 2.39, 95% CI 1.10–5.23; 3 trials, 1335 participants).
Published human study (PubMed / Europe PMC), extracted from its abstract — not a CT.gov-registered trial.
Treatment studies
tested any and symptomatic hemorrhagic transformation; functional outcome (mRS ≤2) at day 90
result Significant positive impact on HT and functional outcome in moderate (HTI=1) and high (HTI≥2) risk patients; symptomatic HT reduced by 21.1% at HTI=4 (p<0.05); effect neutral at HTI=0.
Published human study (PubMed / Europe PMC), extracted from its abstract — not a CT.gov-registered trial.
Treatment studies
tested ALS Functional Rating Scale - revised (ALSFRS-R) at Month 1 (primary); secondary outcomes also assessed
result Cerebrolysin group improved 2.3 points on ALSFRS-R from baseline to Month 1 vs 0.9-point decrease in placebo (P=0.005); effect maintained over 3-month study.
Published human study (PubMed / Europe PMC), extracted from its abstract — not a CT.gov-registered trial.
Treatment studies
tested NIHSS, Fugl-Meyer Assessment Score, GCS, MMSE at admission, discharge, and 90 days
result Intervention group (citicoline+vinpocetine+edaravone+cerebrolysin) showed significant and early improvements in motor and cognitive recovery vs control at discharge and 90 days.
Published human study (PubMed / Europe PMC), extracted from its abstract — not a CT.gov-registered trial.
Treatment studies
tested qEEG indices (DAR, DTABR, TBR) as indicators of neurophysiological recovery
result Significant increases in DAR and DTABR after rTMS + Cerebrolysin; TBR changes inconclusive. Secondary analysis of CAPTAIN-RTMS trial.
Published human study (PubMed / Europe PMC), extracted from its abstract — not a CT.gov-registered trial.
Treatment studies
tested Western Aphasia Battery (primary); NIHSS, modified Rankin Scale, Barthel Index (secondary)
result Cerebrolysin group: WAB mean increase 35.579±16.316 points at day 90 vs placebo; greater NIHSS and Barthel Index improvements; mRS trend favored Cerebrolysin (p=0.105).
Published human study (PubMed / Europe PMC), extracted from its abstract — not a CT.gov-registered trial.
Treatment studies
tested Montreal Cognitive Assessment (MoCA) score and delirium rate (CAM)
result No significant MoCA difference between groups pre/postoperatively; delirium occurred in 3/26 controls vs 0/29 cerebrolysin patients (not statistically significant).
Published human study (PubMed / Europe PMC), extracted from its abstract — not a CT.gov-registered trial.
Treatment studies
tested Glasgow Outcome Scale Extended (GOSE), HADS Depression and Anxiety scores; cost-effectiveness analysis
result Cerebrolysin cost-effective in >80% of moderate TBI patients by GOSE and >95% by HADS depression/anxiety scores, assuming 12-month lasting effect of CAPTAIN II protocol.
Published human study (PubMed / Europe PMC), extracted from its abstract — not a CT.gov-registered trial.
Treatment studies
tested DTI metrics (AD, RD, MD, FA) in infarct core; BBB permeability (PS by PCT); infarct volume at 24h and day 14
result By day 14, IG showed higher AD (contrast 259.05; 95% CI 142.19–375.91), lower BBB permeability PS (−1.41; 95% CI −1.69 to −1.13; p<0.001), and reduced infarct volume vs CG.
Published human study (PubMed / Europe PMC), extracted from its abstract — not a CT.gov-registered trial.
Treatment studies
tested Resting-state EEG relative power spectral density (delta, theta, alpha, beta) and neuropsychological assessments
result Alpha power decreased (p=0.02), delta power increased (p=0.02) across scalp; CRB+sham group: delta δ=0.6 p=0.012, alpha δ=0.6 p=0.064; delta negatively, alpha positively correlated with neuropsychological performance.
Published human study (PubMed / Europe PMC), extracted from its abstract — not a CT.gov-registered trial.
Treatment studies
tested Functional independence (mRS 0–2 at 90 days), secondary ICH, NIHSS at 24h and day 7, Barthel Index at 30 and 90 days, mortality
result mRS 0–2 at 90d: 68% vs 44% (OR 2.7, p=0.016); secondary ICH: 14% vs 40% (RR 0.37, p=0.02); NIHSS day 7 median 3 vs 6 (p=0.01); Cerebrolysin independent predictor OR 7.5 (95%CI 1.8–30.9).
Published human study (PubMed / Europe PMC), extracted from its abstract — not a CT.gov-registered trial.
OpenNCT01059461Phase 2 · 2011 · n=40 · Sahar M.A. Hassanein, MD Hypoxic-Ischemic Encephalopathy
tested Side effects during cerebrolysin therapy (one course).
result Completed; results not posted
Non-randomised; effect size cannot be separated from placebo.
Ischemic Stroke
tested Modified Rankin Scale
result Terminated before completion
Terminated: The goal to match 1000 patients per group could not be achieved with reasonable effort and in reasonable time.
Acute Ischemic Stroke
tested Ordinal modified Rankin Scale (mRS) at 3 months after stroke onset
result Completed; results not posted
OpenNCT04904341Phase 3 · 2021 · n=50 · Military Institute od Medicine National Research Institute Stroke, Ischemic
tested Favorable functional outcome
result In progress (unknown)
Non-randomised; effect size cannot be separated from placebo.
OpenNCT052884652014 · n=5 · Universidad Autonoma de Nuevo Leon Hair Problems
tested Macroscopic evaluation of scalp repigmentation
result Completed; results not posted
Non-randomised; effect size cannot be separated from placebo.
ObseNCT058075032020 · n=56 · Pomeranian Medical University Szczecin TBI (Traumatic Brain Injury)
tested Glasgow Outcome Scale GOS
result Completed; results not posted
OpenNCT060707532023 · n=30 · Shaare Zedek Medical Center Acute Ischemic Stroke
tested Modified Rankin Scale (mRS)
result In progress (unknown)
Non-randomised; effect size cannot be separated from placebo.
OpenNCT06489925Early Phase 1 · 2024 · n=20 · University Hospital Sestre Milosrdnice Basilar Artery Occlusion
tested Percentage of participants in the Cerebrolysin group with the Modified Rankin Scale (mRS) score 0-3 at 90 days post-stroke compared to historical controls
result In progress (unknown)
Non-randomised; effect size cannot be separated from placebo.
OpenNCT070436862025 · n=30 · University Medical Centre Ljubljana Ischemic Stroke, Acute
tested 90-day Action Research Arm Test (ARAT) Score change
result In progress (recruiting)
Non-randomised; effect size cannot be separated from placebo.
Treatment studies
tested cognitive function (MMSE, ADAS-cog+) and global clinical function (response rates)
result MMSE WMD +1.10 (95% CI 0.37–1.82); ADAS-cog+ WMD −4.01 (95% CI −5.36 to −2.66); global function RR 2.71 (95% CI 1.83–4.00); 6 RCTs, n=597
Published human study (PubMed / Europe PMC), extracted from its abstract — not a CT.gov-registered trial.
Treatment studies
tested executive, cognitive, and functional performance (functional/cognitive scales at baseline, 4 months, 7 months)
result Cerebrolysin group (n=11) showed significant improvement vs control: moderate residual disability and significant reduction in need for care at 7-month endpoint.
Published human study (PubMed / Europe PMC), extracted from its abstract — not a CT.gov-registered trial.
Treatment studies
tested serum S100 protein and NSE levels as markers of brain damage
result Cerebrolysin+citicoline corrected neuroglioproliferative markers 1.7–2.7x better than conventional therapy (p<0.01) and 1.2–1.4x better than cerebrolysin+mexidol (p<0.05).
Published human study (PubMed / Europe PMC), extracted from its abstract — not a CT.gov-registered trial.
Treatment studies
tested clinical scales (PANSS, CDSS, CGI-S, HAMD-17) and platelet/erythrocyte glutamate and glutathione metabolism enzyme activities
result Cerebrolysin was one of several adjunctive agents in Gr3 (n=23); outcomes not disaggregated by individual drug. Gr2 (EMHS) showed biochemical normalization; Gr3-specific effects unreported.
Published human study (PubMed / Europe PMC), extracted from its abstract — not a CT.gov-registered trial.
Treatment studies
tested Length of stay, Glasgow Outcome Scale (GOS), mortality
result Cerebrolysin associated with reduced death probability in non-severe TBI (estimate -0.333, SE=0.157, p=0.034) but not severe TBI (p=0.364); better survival with neuromonitoring.
Published human study (PubMed / Europe PMC), extracted from its abstract — not a CT.gov-registered trial.
Treatment studies
tested Symptomatic and any hemorrhagic transformation; functional outcome (mRS) at day 90
result Positive impact on HT and functional outcome in moderate (HTI=1) and high (HTI≥2) risk patients; symptomatic HT reduced by 14.3% (p<0.001) in high-risk; neutral effect in low-risk (HTI=0).
Published human study (PubMed / Europe PMC), extracted from its abstract — not a CT.gov-registered trial.
Treatment studies
tested anaphylactic reaction following IV cerebrolysin administration
result Fulminant anaphylaxis after IV cerebrolysin in 85-year-old male with subacute stroke; confirmed by labs; vital functions restored with targeted measures.
Published human study (PubMed / Europe PMC), extracted from its abstract — not a CT.gov-registered trial.
Treatment studies
tested oral apraxia recovery; ability to orally intake regular diet
result Marked recovery of oral apraxia within short period; patient progressed from tube feeding to oral intake of regular diet after IV cerebrolysin + intensive rehabilitation starting 23 days post-onset.
Published human study (PubMed / Europe PMC), extracted from its abstract — not a CT.gov-registered trial.
Treatment studies
tested Cognitive deficit progression and conversion rate to dementia over 3 years
result Annual Cerebrolysin courses (20 ml IV ×20/year) showed lower cognitive deficit progression and significantly lower dementia conversion rate vs untreated group over 3 years.
Published human study (PubMed / Europe PMC), extracted from its abstract — not a CT.gov-registered trial.
Treatment studies
tested Glasgow Outcome Scale (GOS), length of stay (LOS), mortality
result Cerebrolysin improved mortality in combination with neuromonitoring in severe SAH (n=26 vs n=21); no effect on raw GOS scores or LOS.
Published human study (PubMed / Europe PMC), extracted from its abstract — not a CT.gov-registered trial.
Treatment studies
tested mRS 0-2 at day 90 (primary); NIHSS, MoCA, hemorrhagic transformation rate, mortality (secondary)
result mRS 0-2 at day 90: 64% vs 34.7% (control); hemorrhagic transformation: 20% vs 57.3%; OR for favorable mRS avoiding HT=2.75 (95% CI 1.17–6.45, p=0.002).
Published human study (PubMed / Europe PMC), extracted from its abstract — not a CT.gov-registered trial.
Treatment studies
tested hemorrhagic transformation (symptomatic and any HT) within 14 days; optimal anticoagulation resumption timing
result Cerebrolysin reduced symptomatic HT (HR 0.245; 95% CI 0.072–0.837; p=0.02) and any HT (HR 0.543; 95% CI 0.297–0.991; p=0.032); enabled earlier safe anticoagulation resumption in high-risk patients by day 2 vs days 3–5.
Published human study (PubMed / Europe PMC), extracted from its abstract — not a CT.gov-registered trial.
Treatment studies
tested Functional independence (mRS 0-2 at 90 days), NIHSS at 24h and day 7, secondary ICH, Barthel Index at 30 and 90 days, mortality
result mRS 0-2 at 90d: 68% vs 44% (p=0.016, OR 2.7); secondary ICH: 14% vs 40% (p=0.02, RR 0.37); NIHSS day 7 median 3 vs 6 (p=0.01); Barthel at 3mo: 86 vs 75 (p=0.01).
Published human study (PubMed / Europe PMC), extracted from its abstract — not a CT.gov-registered trial.
Treatment studies
tested modified Rankin Scale, infarct volume, symptomatic intracranial hemorrhage
result Systematic review of 10 RCTs; cerebrolysin was one of several adjunctive neuroprotective agents evaluated alongside reperfusion therapy; results heterogeneous across interventions.
Published human study (PubMed / Europe PMC), extracted from its abstract — not a CT.gov-registered trial.
Treatment studies
tested mRS at 90 days (primary); NIHSS at day 21 & 90, mRS at day 21, excellent recovery (mRS 0-1), functional independence (mRS 0-2), MoCA at 90 days (secondary)
result Cerebrolysin superior on primary mRS-90 (MW 0.6157, 95% CI 0.5910–0.6404, P<0.0001) and all secondary endpoints; MoCA MW 0.5530 (P<0.0001); no safety differences.
Published human study (PubMed / Europe PMC), extracted from its abstract — not a CT.gov-registered trial.
Treatment studies
tested NIHSS score and Barthel Index at Day 14
result Adjuvant group NIHSS: 9.90±2.90 → 3.40±1.40; standard group: 10.10±2.80 → 4.80±1.30 (t=6.19, p<0.001). BI also significantly better in adjuvant group.
Published human study (PubMed / Europe PMC), extracted from its abstract — not a CT.gov-registered trial.
Treatment studies
tested neuropsychiatric symptoms, cognitive function
result Patient showed significant improvement in post-HSE neuropsychiatric symptoms following Cerebrolysin administration in the post-acute phase after acyclovir/dexamethasone.
Published human study (PubMed / Europe PMC), extracted from its abstract — not a CT.gov-registered trial.
Treatment studies
tested 90-day mortality (safety); mRS 0–2 at 90 days (efficacy); NIHSS, ordinal mRS shift, Barthel Index, hematoma expansion, SAEs
result Protocol paper only; no results reported. 88 patients randomized 1:1 to cerebrolysin 50 mL IV/day ×14 d + standard care vs. standard care alone; ultra-early window ≤6 h.
Published human study (PubMed / Europe PMC), extracted from its abstract — not a CT.gov-registered trial.
Treatment studies
tested neurological function at 6 months, mortality, ICU and hospital length of stay
result No statistically significant difference in neurological function or mortality at 6 months; combination group trended toward better outcomes but had more severe baseline injury profiles.
Published human study (PubMed / Europe PMC), extracted from its abstract — not a CT.gov-registered trial.
Treatment studies
tested neurological recovery, functional independence, quality of life
result Cerebrolysin included as neuroprotective agent in perioperative multimodal management; abstract describes rationale and approach but reports no quantified outcome data.
Published human study (PubMed / Europe PMC), extracted from its abstract — not a CT.gov-registered trial.
Treatment studies
tested hemorrhagic transformation incidence and hazard trajectory over 14 days
result In high-risk patients, Cerebrolysin reduced symptomatic HT (HR 0.245; 95% CI 0.072-0.837; p=0.020) and any HT (HR 0.543; 95% CI 0.297-0.991; p=0.032); advanced risk-equilibrium by ~1-2 days.
Published human study (PubMed / Europe PMC), extracted from its abstract — not a CT.gov-registered trial.
Treatment studies
tested motor function (MRC, mRS, Barthel, Berg, Rivermead, MAS, gait), aphasia (Wasserman Scale), neuropsychological testing
result 2-pt MRC muscle strength gain, 1-pt tone reduction, improved gait; Wasserman aphasia score 48→40; improved auditory-verbal memory and praxis
Published human study (PubMed / Europe PMC), extracted from its abstract — not a CT.gov-registered trial.
Treatment studies
tested 12-month functional independence (mRS 0–2), mRS shift, Barthel Index, institutional care requirement, mortality
result Cerebrolysin associated with higher 12-month functional independence (aOR 6.10, 95% CI 1.64–22.66), favorable mRS shift (cOR 3.57), lower institutional care (6% vs 19%, NNT 8), higher BI (92 vs 83).
Published human study (PubMed / Europe PMC), extracted from its abstract — not a CT.gov-registered trial.
Treatment studies
tested recovery of speech functions
result ESCAS study: combined speech therapy + Cerebrolysin accelerates recovery of speech functions vs. speech therapy alone in post-stroke aphasia rehabilitation.
Published human study (PubMed / Europe PMC), extracted from its abstract — not a CT.gov-registered trial.
Treatment studies
tested CRS-R score at discharge (primary); Barthel Index, modified Rankin Scale, 6-month survival (secondary)
result CRS-R 20.3±2.7 vs 16.4±2.1 (p=0.013); 6-month survival 59.4% vs 27.8% (p<0.001); higher BI and lower mRS in cerebrolysin group.
Published human study (PubMed / Europe PMC), extracted from its abstract — not a CT.gov-registered trial.
Preclinical / mechanistic research
tested mouse · Effects and mechanism of cerebroprotein hydrolysate on learning and memory ability in mice.
result Preclinical publication captured from PubMed/Europe PMC; effect details require paper-level extraction.
Preclinical / mechanistic research
tested mouse · Cerebroprotein hydrolysate-I protects senescence-induced by D-galactose in PC12 cells and mice.
result Preclinical publication captured from PubMed/Europe PMC; effect details require paper-level extraction.
Preclinical / mechanistic research
tested mouse · Cerebroprotein Hydrolysate-I Inhibits Hippocampal Neuronal Apoptosis by Activating PI3K/Akt Signaling Pathway in Vascular Dementia Mice.
result Preclinical publication captured from PubMed/Europe PMC; effect details require paper-level extraction.
Preclinical / mechanistic research
tested mouse · Cerebroprotein hydrolysate injection is involved in promoting long-term angiogenesis, vessel diameter and density after cerebral ischemia in mice.
result Preclinical publication captured from PubMed/Europe PMC; effect details require paper-level extraction.
Preclinical / mechanistic research
tested mouse · Cerebroprotein hydrolysate attenuates neurodegenerative changes in Alzheimer's mice model <i>via</i> ferroptosis pathway.
result Preclinical publication captured from PubMed/Europe PMC; effect details require paper-level extraction.
Preclinical / mechanistic research
tested rat · Fucoidan (A Sulfated Polysaccharide) and Cerebroprotein in Combination Alleviate the Neuroinflammation-mediated Neural Damage and Functional Deficits in the Focal Cerebral Ischemia Model of Rat.
result Preclinical publication captured from PubMed/Europe PMC; effect details require paper-level extraction.
Preclinical / mechanistic research
tested rat · Cerebrolysin potentiates the antidepressant effect of lithium in a rat model of depression.
result Preclinical publication captured from PubMed/Europe PMC; effect details require paper-level extraction.
Preclinical / mechanistic research
tested rat · Acute Combined Cerebrolysin and Nicotinamide Administration Promote Cognitive Recovery Through Neuronal Changes in the Hippocampus of Rats with Permanent Middle Cerebral Artery Occlusion.
result Preclinical publication captured from PubMed/Europe PMC; effect details require paper-level extraction.
Preclinical / mechanistic research
tested mouse · Cerebroprotein hydrolysate-I ameliorates cognitive dysfunction in APP/PS1 mice by inhibiting ferroptosis via the p53/SAT1/ALOX15 signalling pathway.
result Preclinical publication captured from PubMed/Europe PMC; effect details require paper-level extraction.
Preclinical / mechanistic research
tested rat · Cerebrolysin Induces Motor Recovery Along with Plastic Changes in Motoneurons and an Increase in GAP43 Protein in the Ventral Spinal Cord Following a Kainic Acid Excitotoxic Lesion in the Rat Motor Cortex.
result Preclinical publication captured from PubMed/Europe PMC; effect details require paper-level extraction.
Preclinical / mechanistic research
tested mouse · Effects of cerebrolysin on behavioral changes and the tryptophan-kynurenine pathway in the prefrontal cortex of male mice in the ketamine model of schizophrenia.
result Preclinical publication captured from PubMed/Europe PMC; effect details require paper-level extraction.
Preclinical / mechanistic research
tested mouse · Cerebrolysin Ameliorates Age-Induced Dendritic Spine Degeneration and Memory Decline in C57BL6 Mice.
result Preclinical publication captured from PubMed/Europe PMC; effect details require paper-level extraction.
Preclinical / mechanistic research
tested Troxerutin and Cerebroprotein Hydrolysate Injection Protects Neurovascular Units from Oxygen-Glucose Deprivation and Reoxygenation-Induced Injury <i>In Vitro</i>.
result In-vitro publication captured from PubMed/Europe PMC; assay details require paper-level extraction.
Preclinical / mechanistic research
tested Neuroprotection by Cerebrolysin and Citicoline Through the Upregulation of Brain-Derived Neurotrophic Factor (BDNF) Expression in the Affected Neural Cells: A Preliminary Clue Obtained Through an In Vitro Study.
result In-vitro publication captured from PubMed/Europe PMC; assay details require paper-level extraction.